RSS

CYDY CytoDyn Inc

Mod: mightycydy Asst: HHIGambler,CaptnAmerca
Last Post: 8:00 PM
Followers: 440
Posts Today: 30
Views Today: 35924

CYDY Stock Quote & Tools

$0.2600 ▲ +0.0201 (+8.38%) As of Oct 23, 3:59 PM EDT
Last0.2600
$ Chg0.0201
Open0.2400
High0.2782
Beta1.4964
Year High0.397
Market Cap382.07M
P/B Ratio-2.68
EPS-0.04
Avg Vol (30d)2.08M
Volume3.86M
% Chg+8.38%
Prev Close0.2399
Low0.2340
VWAP0.25950
Year Low0.183
Total Shares1.47B
Shares Out1.47B
Float1.36B
ExchangeOTCQB
Healthcare Biotechnology & Life Sciences
Company Profile Buy Rating Time & Sales News Filings Financials

CYDY Stock Message Board Discussion

4 Pinned Posts
Leronlimab (Pro 140) Cliff Notes What is it? Leronlimab is a humanized monoclo (43) by trding
Leronlimab Regulator List (a work in progress) = upregulation = downregulation a-SMA (21) by ohm20
EIND: Information to Submit to Doctors Leronlimab a humanized monoclonal antibody binds CCR5, (38) by ohm20
Procedure to request compassionate use LeronlimabReceived this email from Dr. Jay. CytoDyn can (12) by FKAdamF.
  1. calstang

    Here is the problem I have with selling vs holding vs buying more........ Nader should

    (3)
  2. Riztheinvestor

    Pretty obvious IMO. The law isnt enforced anymore trust me I know its kinda my job.... Yes Im

    (1)
  3. CTMedic

    Goldenisia, Quite a constellation of symptoms, and likely divergent/heterogenous pathology as Dr

    (4)
  4. dfwl28

    the ROT imo, was an unnecessary ingredient as there are hundreds of drugs out there approved with

    (4)
  5. SizzlChest

    And Big Pharma owns the press

    (5)
  6. craigakess

    You're not disagreeing with my post overall by any means. You seem to be agreeing that people are

    (1)
  7. SizzlChest

    The reason I disagree with your post is that people realize the FDA only approves vaccines with no

    (9)
  8. SAF

    Why do you think they arent?

  9. craigakess

    The reason I disagree with you about "buyers should be gobbling this stock up" is because with a

    (5)
  10. MicMac

    I think I read that one of his long hauler study participants was sent to Dr R in Florida to join

    (1)
  11. HCIT

    Yep, my bad sunclouds, should have been 2.30, wooooppppsssy - GLTU HCIT

  12. JLang

    That's fine, the exchange went: Me suggesting that CytoDyn is the one that has the drug,

    (1)
  13. Shelly2626

    Totally agree on that statement....many have bought and are holding ..many traders been burned ...I

    (1)
  14. calstang

    $2.31 per share? EUA on the table? 31.8% reduction in critical deaths 65 and younger vs SOC? HIV

    (14)
  15. nicehedges

    ScienceDirect Paper from yesterday:

    (13)
  16. TechGuru

    Z_Smith, Very interesting post. There rare several aspects of the ROT that we (me for sure)

    (13)
  17. Cycl2R

    If somebody needs comfort and sleep sweetly I suggest you keep a paper by your bed-table and read a

  18. calstang

    Goldenissla wrote: I can see this long haulers trial getting confusing and leading to many other

    (2)
  19. ibmiked

    Correction: non-commercial grade. I was going from memory.

    (1)
  20. z_smith01

    The following is my understanding re: ROT. The initial COMBO trial was at 350mg and there were

    (18)
  21. JLang

    The cytokine storm leaves a mess behind it; some stay in circulation for months, trigger periodic

    (4)
  22. Goldenisla

    I can see this long haulers trial getting confusing and leading to many other trials. In long

  23. ClosetInvestor

    Saying he has commercial grade LLMab is a fallacy, not an argument. Correct, its not

  24. JLang

    Saying he has commercial grade LLMab is a fallacy, not an argument

    (1)
  25. Number1Stocker

    New FDA update for Longhaulers

  26. ohm20

    Any lab that is setup for receptor occupancy can do tests for CCR5 very easily. As I said it's

    (4)
  27. TechGuru

    Good day to all. Listened to the last (23/3/2021) conference with attention. The Oncology

    (28)
  28. MicMac

    unfortunate that they a) spelled Cytodyn incorrectly and b) stated that the trial would be 91 weeks

  29. Joja

    https://trialsitenews.com/trial-sites-in-miami-gainesville-ga-test-leronlimab-on-long-haulers-two-w

  30. ibmiked

    I dont engage in straw arguments and I never said that he was treating patients with Leronlimab.

    (3)
  31. JLang

    How many covid sufferers can/has he treated with that industrial grade Leronlimab? The contract is

    (1)
  32. ClosetInvestor

    CCR5 occupancy tests are standard fare. No one has to develop one. NP said himself, back in

    (1)
  33. ohm20

    Lets suppose that some lab somewhere is working for CYDY on a CCR5 receptor occupancy test.

    (3)
  34. PTM1

    Reminiscent of the attitude towards the sufferers from chronic Lyme disease. To paraphrase that

    (5)
  35. ibmiked

    From JLang, "What Patterson doesn't have is Leronlimab. Renders him fairly moot." That's not

    (1)
  36. CTMedic

    Goldenisia,not testing positive and not having the disease are not the same. The claim that long

    (7)
  37. JLang

    LH trial requires proof of positive Sars2 markers or antibodies in addition to symptoms, and

    (6)
  38. JLang

    Gaslighting Long Haulers, nice look there, WSJ.. it's like KFC having to drop the "chicken".. you

    (5)
  39. nothingspecial

    I read an article about the 98 symptoms of LH. I probably had over half. I attributed half of

    (1)
  40. nothingspecial

    Am happy CYDY decided to do the CD17 trial. May or may not lead to any sort of approval or

    (4)
  41. Goldenisla

    https://www.wsj.com/articles/the-dubious-origins-of-long-covid-11616452583 This article says

  42. sean007

    Many on this board and likely elsewhere have bemoaned the fact that Dr B. Patterson is "not in the

    (5)
  43. Goosebumps

    Quote Havasu78 "-CD16 - Slam dunk trial will take care of the above if not granted sooner "

    (3)
  44. havasu78

    "Kelly: Covid critical pales in comparison to opportunity in long haulers, long haulers absolutely

    (1)
  45. havasu78

    Indeed the potential of leronlimab may be unlimited. CCR5 may prove the master and commander of

  46. JLang

    Good points about RO, I tend to agree, and non-mITT is a valid point as well, but not everyone said

    (1)
  47. havasu78

    "Risk comes from not knowing what you're doing." This idea, on the other hand, I do fully

  48. havasu78

    "Real lawsuits are behind us, the others are fake news." Another idea that totally confuses me.

    (2)
  49. havasu78

    Here is another one that irritates me. "-CD16 - Slam dunk trial will take care of the above if

    (2)
  50. havasu78

    ok, i'll bite. How exactly are "receptor occupancy concerns addressed, underway, and will be

    (4)

Top 10 Most Recent News Articles

Symplr's Strategic Refinancing: A Shot in the Arm

Updated Category News Views 5

Symplr's Financial Revamp: What It Means You're not often floored by a refinancing move, but symplr's announcement on October 23 sure seems like a savvy maneuver. For a company that's already a lynchpin in healthcare operations, extending debt maturities and juicing up liquidity is like an adrenaline shot to the ticker. And for me, it's the confidence from heavyweights...

Continue Reading
Anavex Faces Securities Lawsuit: Investor Implications

Updated Category News Views 4

Storm Clouds Over Anavex: What Investors Need to Know If you've got a slice of Anavex Life Sciences Corp. (NASDAQ: AVXL) in your portfolio, the latest chapter of their legal saga feels less like a twist and more like a twist of the knife. These lawsuits often come out of left field for investors, but this one seems like a slow train that’s been gathering steam for a...

Continue Reading
Rich McLaughlin Takes Helm of WFUV Radio

Top 5 Most Recently Viewed Articles

Evolving Trends in the Automotive Market: Ford vs Rivian

Updated Category News Views 187

Shifting Trends in the Automotive Market The automotive market is experiencing significant changes. After years of steady growth for battery-powered electric vehicles (EVs), the sector has recently hit a plateau. Just a year ago, new unit sales for EVs were on the rise, but in the first quarter of 2024, that growth rate fell to zero, indicating that the number of EVs sold...

Continue Reading
Monthly Financial Summary of the United States Brent Oil Fund

Updated Category News Views 61

Back in 2024, the United States Brent Oil Fund, LP (NYSE Arca:BNO), dropped its monthly financial report, laying bare the numbers behind its shaky performance. Traders were already on edge with oil prices yo-yoing all over the place, and this disclosure didn’t ease their worries. With total returns plummeting to -5.31% for the month and a whopping -11.79% over three...

Continue Reading
Understanding the Upcoming Treasury Bond Auction Process

Updated Category News Views 114

Treasury Bond Auction Overview As investors look towards various financial instruments, the upcoming Treasury bond auction represents an appealing opportunity. The RIKS 29 0917 bonds with ISIN IS0000037711 are set to be auctioned soon, paving the way for strategic investments in a stable financial environment. Key Details About RIKS 29 0917 Bonds This specific bond...

Continue Reading
Significant Changes in U.S. Down Payment Trends Dissected

Updated Category News Views 149

Understanding Recent Down Payment Trends Across the U.S. As homebuyers continue to face fluctuating market conditions, down payments have seen substantial changes, particularly across various regions of the United States. While the Northeast and Midwest witness notable increases in median down payments, certain Southern states are grappling with declines in their...

Continue Reading
Exploring the Growth of Printed Electronics Industry to 2032

Updated Category News Views 200

Future Prospects of Printed Electronics Market The global printed electronics market is rapidly evolving, with significant potential projected over the coming years. Industry forecasts suggest that the market will be valued at approximately US$ 62.57 billion by 2032, showcasing an impressive compound annual growth rate (CAGR) of 18.5% from 2025 to 2032. Key Drivers of...

Continue Reading